The Food and Drug Law Institute, the premier educational organization in the field of food and drug law, announced today that President and Chief Executive Officer Susan C. Winckler will step down ...read more

FDA’s Social Media Draft Guidance Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on February 2014 by Davina Rosen Marano, Editor, FDLI

“Do We ‘Like’ FDA’s ‘First Social Media Guidance’ or is it Nothing to ‘Tweet’ About?” is the timely topic addressed by Daniel Kracov, Partner, ...read more

FDA’s Postmarket Surveillance of Medical Devices Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on December 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

“Is FDA’s Decision to Ramp-up the Postmarket Surveillance of Medical Devices the Best Way to Make Devices Safe?” is the topic addressed by Thomas R. McLean, M.D., J.D., FACS and Alexander B. McLean...read more

The Food and Drug Law Institute To Honor Axelrad, Gibbs, Holcombe, Kingham

Posted on December 2013 by Michel Levin-Epstein, Editor-in-Chief, FDLI

Honorees Will Receive Distinguished Service and Leadership Awards at Holiday Reception December 10 December 5, Washington, DC -- The Food and Drug Law Institute will honor four outstanding food and...read more

“Can FDA Accelerate Clinical Trial Timelines and Completion Using Documented cGMP Processes?” is the topic addressed by Anton Lewis Usala, M.D., President and CEO, CTMG, Inc. and Neil D...read more

Constitutionality of State Biosimilar Substitution Bills Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on September 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

“Do Pending State Biosimilar Substitution Bills Violate State Constitutional Law Principles of Non-Delegation and Incorporation by Reference?” is the timely topic addressed by Neal Park...read more

Social Media Guidance from FDA Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on June 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

read more

read more

read more

read more